Finanzen von Kezar Life Sciences Inc (KZR)KZRKezar Life Sciences Inc

Evaluating the bottom line, Kezar Life Sciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -53.75%, provide a clear picture of how effectively KZR converts its operational activities into shareholder value.

In the context of the broader market, KZR competes directly with industry leaders such as TIL and SGMO. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, KZR's gross margin of N/A stands against TIL's N/A and SGMO's 100.00%. Such benchmarking helps identify whether Kezar Life Sciences Inc is trading at a premium or discount relative to its financial performance.

In Q4 2025, revenue remained at 0 with no growth. Net income declined by 28.05% YoY to -$14,546,000, and EPS dropped by 28.16% YoY to -1.99. Gross margin remained at 0, showing no improvement.